do you lose more weight on mounjaro or semaglutide vs. Ozempic: Effectiveness, Side Effects & Cost Comparison Powerful new obesity drug poised

Description

Means lower Emerging observational studies and small interventional trials suggest that GLP-1 RAs may be used in patients with advanced CKD with preserved glucose-lowering efficacy and a relatively low intrinsic risk of hypoglycemia compared with insulin and sulfonylureas ( Semaglutide has recently received expanded regulatory approval for use in patients with T2DM and CKD, reflecting growing confidence in its renal safety profile and potential kidney-protective benefits ( In Saudi Arabia, T2DM prevalence is among the highest worldwide and is accompanied by high rates of obesity, cardiovascular disease, and CKD ( Therefore, this multicenter retrospective study aimed to evaluate the real-world safety and effectiveness of semaglutide in patients with ESRD receiving care at Saudi tertiary healthcare centers, with a focus on glycemic outcomes, body weight changes, cardiovascular events, renal safety, and treatment tolerability

Severe Joint Pain: Some patients may experience disabling arthralgia that resolves upon discontinuation

WildingJPHBatterhamRLCalannaSDaviesMVan GaalLFLingvayIet al

A change in taste while using Mounjaro can come from two different sources: the medication itself or the bodys response to weight loss

Body weight change from baseline to 13 weeks was 14.7% with 15 mg VK2735, 12.9% with 10 mg VK2735, 10.9% with the 5 mg dose and 9.1% with the 2.5 mg dose vs